Table 5.
sNfL and sGFAP in Long-COVID patients with neurological associated symptoms such as headache (sNfL n = 16, sGFAP n = 15), fatigue (sNfL n = 21, sGFAP n = 14), anosmia (sNfL n = 19, sGFAP n = 18) and ageusia (sNfL n = 19, sGFAP n = 19) prior to a SARS-CoV2 infection and during the Long-COVID period. The Wilcoxon test was used to assess group differences.
| sNfL before Infection vs. after Infection | sGFAP before Infection vs. after Infection | |||||
|---|---|---|---|---|---|---|
| Symptoms | Median | IQR | p-Value | Median | IQR | p-Value |
| headache | 6.9 to 6.9 | 5.8 to 8.4 vs. 5.5 to 7.8 |
p = 0.29 | 67.7 to 66.9 | 52.0 to 79.5 vs. 45.2 to 73.5 |
p = 0.71 |
| fatigue | 7.3 vs. 6.9 | 5.8 to 9.3 vs. 5.5 to 8.4 |
p = 0.17 | 66.8 to 69.9 | 47.4 to 82.7 vs. 51.8 to 86.0 |
p = 0.39 |
| anosmia | 7.3 vs. 6.7 | 5.3 to 8.8 vs. 50.6 to 8.3 |
p = 0.35 | 59.0 vs. 60.9 | 47.9 to 74.6 vs. 50.1 to 70.1 |
p = 0.35 |
| ageusia | 6.7 vs. 6.6 | 5.3 to 8.6 vs. 5.6 to 7.9 |
p = 0.23 | 61.7 vs. 60.7 | 49.5 to 76.8 vs. 45.3 to 71.0 |
p = 0.16 |